Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: Fludarabine Phosphate, Tacrolimus, Thiotepa, Total-Body Irradiation (TBI), Magnetic Affinity Cell Sorting, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation; Drug · Radiation · Other + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 14 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Seattle, Washington

Conditions: Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, MS (Multiple Sclerosis), MS, Multiple Sclerosis (MS) Secondary Progressive
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Dry Eye Syndromes
Interventions: MIM-D3 Ophthalmic Solution, Vehicle; Drug
Lead sponsor: Mimetogen Pharmaceuticals USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Waterbury, Connecticut • Lewiston, Maine • Andover, Massachusetts + 2 more

Conditions: Healthy
Interventions: Diclofenac Sodium Gel; Drug
Lead sponsor: Amzell; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Chronic Hepatitis B
Interventions: TDF, Vesatolimod, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 6 more

Conditions: Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
Interventions: CC-122; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 17
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Early Onset Scoliosis, Congenital Spinal Deformities, Infantile Idiopathic Scoliosis, Neuromuscular Spinal Deformity, Syndromic Spinal Deformity, Thoracic Insufficiency Syndrome
Interventions: Not listed
Lead sponsor: Growing Spine Study Group; Other
Eligibility: 1 Day to 18 Years
Enrollment: 2,602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 19
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more

Conditions: Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, LOPD, Lysosomal Storage Diseases, Acid Maltase Deficiency
Interventions: Neutralizing Antibody to SPK-3006 capsid; Diagnostic Test
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Phoenix, Arizona • Orange, California • Kansas City, Kansas + 3 more

Conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions: OLAPARIB, Single agent chemotherapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 22
States / cities: Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 19 more

Conditions: Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
Interventions: AZD6244, Dacarbazine, Erlotinib, Docetaxel, Temsirolimus; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 4
States / cities: Detroit, Michigan • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: COVID-19, ARDS, Human, Stem Cells, Regeneration
Interventions: MRG-001, Placebo; Drug
Lead sponsor: MedRegen LLC; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Psoriatic Arthritis
Interventions: AbGn-168H; Biological
Lead sponsor: AbGenomics B.V Taiwan Branch; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: La Jolla, California • Palo Alto, California • Sarasota, Florida + 4 more

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 16
States / cities: Atlanta, Georgia • Dunwoody, Georgia • Fort Wayne, Indiana + 12 more

Conditions: Metastatic Melanoma
Interventions: Obatoclax Mesylate, Temozolomide; Drug
Lead sponsor: Gemin X; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parkinson Disease
Interventions: KM-819, Placebo; Drug
Lead sponsor: FAScinate Therapeutics Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 314 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Glendale, California • San Diego, California • Royal Oak, Michigan

Conditions: Herpes Zoster
Interventions: HZ/su vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 3,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Phoenix, Arizona • Elkridge, Maryland • Charlotte, North Carolina + 5 more

Conditions: Symptomatic Cervical Disc Disease
Interventions: prodisc C SK and/or Vivo, Mobi-C Cervical Disc; Device
Lead sponsor: Centinel Spine; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 30
States / cities: Flagstaff, Arizona • Beverly Hills, California • Los Angeles, California + 24 more

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: Tedisamil sesquifumarate; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 4
States / cities: Los Angeles, California • Santa Ana, California • Honolulu, Hawaii + 1 more

Conditions: Skin Wrinkling
Interventions: Emervel Deep Lidocaine, Juvederm Ultra Plus; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Lower Respiratory Tract Infection
Interventions: Azithromycin, Placebo, VIDAS B.R.A.H.M.S Procalcitonin Test (PCT); Drug · Other · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Atlanta, Georgia • Decatur, Georgia • Durham, North Carolina + 1 more

Conditions: Healthy Volunteers
Interventions: OLT1177 Gel, Placebo gel; Drug
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Crohn's Disease
Interventions: Nitazoxanide, Placebo; Drug · Other
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 13
States / cities: Tampa, Florida • Zephyrhills, Florida • Marietta, Georgia + 10 more

Conditions: Meningococcal Meningitis
Interventions: MenACWY-CRM conjugate vaccine, Licensed comparator; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 389 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 32
States / cities: Birmingham, Alabama • Fremont, California • Fresno, California + 21 more

Conditions: Healthy
Interventions: GSI-953; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

The Treatment of Progressive Early Onset Spinal Deformities: A Multi-Center Outcome Study

Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

aHUS Observational Long Term Follow-Up

A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects

Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds

Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level

Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects

Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population